Results 11 to 20 of about 5,237 (222)

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors [PDF]

open access: goldMicroorganisms, 2021
Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus.
Lana Langendries   +3 more
doaj   +6 more sources

Family Cluster of Mayaro Fever, Venezuela [PDF]

open access: diamondEmerging Infectious Diseases, 2004
A cluster of protracted migratory polyarthritis involving four adult family members occurred in January 2000 after a brief overnight outing in a rural area of Venezuela. Laboratory testing demonstrated Mayaro virus as the cause of the cluster.
Jaime R. Torres   +5 more
doaj   +4 more sources

Mayaro Virus Disease [PDF]

open access: hybridJournal of Human Virology & Retrovirology, 2014
Mayaro virus produces a nonspecific, sublethal disease in man with symptoms that are often confused with dengue. The symptoms of arthralgia, often associated with these viral infections, can cause an incapacitating disability. To date, outbreaks have been localized and sporadic within the Pan-Amazonia forest since its first isolation in 1954 ...
Salvatore G. De-Simone
openalex   +2 more sources

Emerging alphaviruses in the Americas: Chikungunya and Mayaro [PDF]

open access: diamondRevista da Sociedade Brasileira de Medicina Tropical, 2014
Chikungunya virus (CHIKV) and Mayaro virus (MAYV) are emergent arthropod-borne viruses that produce outbreaks of acute febrile illness with arthropathy. Despite their different continental origins, CHIKV and MAYV are closely related and are components of the Semliki Forest Complex of the Alphavirus (Togaviridae).
Mário Luis Garcia de Figueiredo   +1 more
openalex   +8 more sources

Mayaro Virus in Wild Mammals, French Guiana [PDF]

open access: diamondEmerging Infectious Diseases, 2003
A serologic survey for Mayaro virus (Alphavirus, Togaviridae) in 28 wild nonflying forest mammal species in French Guiana showed a prevalence ranging from 0% to 52% and increasing with age. Species active during the day and those who spent time in trees were significantly more infected, results consistent with transmission implicating diurnal ...
Benoı̂t de Thoisy   +4 more
openalex   +5 more sources

Effect of Oral Infection of Mayaro Virus on Fitness Correlates and Expression of Immune Related Genes in Aedes aegypti [PDF]

open access: goldViruses, 2020
Mayaro virus is a mosquito-borne Alphavirus endemic to forests of tropical South America with a sylvatic cycle involving non-human primates and Haemagogus mosquitoes.
Barry W. Alto   +4 more
doaj   +2 more sources

Mouse Models of Mayaro Virus

open access: yesViruses, 2023
Mayaro virus (MAYV), the etiologic agent of Mayaro fever, leads patients to severe myalgia and arthralgia, which can have a major impact on public health in all the countries where the virus circulates. The emergence and dissemination of new viruses have
Rafael Borges Rosa   +4 more
doaj   +3 more sources

Virus Mayaro: un arbovirus reemergente en Venezuela y Latinoamérica

open access: diamondBiomédica: revista del Instituto Nacional de Salud, 2012
El virus Mayaro produce una enfermedad de síntomas inespecíficos y subletales, frecuentemente confundida con dengue, con síntomas de artralgias que pueden generar incapacidad laboral.
Manuel Muñoz, Juan Carlos Navarro
doaj   +3 more sources

Mayaro virus proteins [PDF]

open access: yesMemorias do Instituto Oswaldo Cruz, 1993
Mayaro virus was grown in BHK-21 cells and purified by centrifugation in a potassium-tartrate gradient (5-50%). The electron microscopy analyses of the purified virus showed an homogeneous population of enveloped particles with 69 ñ 2.3 nm in diameter ...
J. M. S. Mezencio, M. A. Rebello
doaj   +5 more sources

Mayaro fever: A brief review on the immune profile

open access: yesAsian Pacific Journal of Tropical Biomedicine, 2020
Mayaro virus is an emergent alphavirus that infects humans, leading to Mayaro fever. Approximately fifty percent of infected patients develop arthritis symptoms in the recovery phase, a phase that can last up to a year.
Jean Moisés Ferreira   +3 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy